Clinical Trial Update: MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents [NA]

View source ↗

Summary

A completed clinical trial evaluating MGMT enzyme status as a predictive factor for response to alkylating agents in neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Neuroendocrine Tumors | NA | Status: COMPLETED